BIOMARIN PHARMACEUTICAL INC Derivative Asset, Fair Value, Gross Asset
BIOMARIN PHARMACEUTICAL INC (BMRN) had Derivative Asset, Fair Value, Gross Asset of $45.85 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Offsetting
us-gaap:DerivativeFairValueOfDerivativeAsset · last filed 2026-08-06
- 2026-06-30: Derivative Asset, Fair Value, Gross Asset $45.85M.
- 2026-03-31: Derivative Asset, Fair Value, Gross Asset $35.06M.
- 2025-12-31: Derivative Asset, Fair Value, Gross Asset $25.66M.
- 2025-09-30: Derivative Asset, Fair Value, Gross Asset $24.59M.
| Period end | Derivative Asset, Fair Value, Gross Asset |
|---|---|
| 2026-06-30 | $45.85M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $35.06M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $25.66M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $24.59M 10-Q · filed 2025-10-28 |
| 2025-06-30 | $22.72M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $37.47M 10-Q · filed 2025-05-02 |
| 2024-12-31 | $79.64M 10-K · filed 2026-02-26 |
| 2024-09-30 | $19.32M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $38.19M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $15.36M 10-Q · filed 2024-04-26 |
| 2023-12-31 | $9.06M 10-K · filed 2025-02-24 |
| 2023-09-30 | $34.10M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $18.84M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $15.59M 10-Q · filed 2023-04-28 |
| 2022-12-31 | $23.00M 10-K · filed 2024-02-26 |
| 2022-09-30 | $61.14M 10-Q · filed 2022-10-28 |
| 2022-06-30 | $42.52M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $24.60M 10-Q · filed 2022-04-29 |
| 2021-12-31 | $22.77M 10-K · filed 2023-02-27 |
| 2021-09-30 | $16.45M 10-Q · filed 2021-10-29 |
| 2021-06-30 | $12.70M 10-Q · filed 2021-07-30 |
| 2021-03-31 | $15.27M 10-Q · filed 2021-04-30 |
| 2020-12-31 | $9.50M 10-K · filed 2022-02-25 |
| 2020-09-30 | $18.17M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $36.37M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $47.26M 10-Q · filed 2020-05-01 |
| 2019-12-31 | $33.59M 10-K · filed 2021-02-26 |
| 2019-09-30 | $52.86M 10-Q/A · filed 2019-11-04 |
| 2019-06-30 | $29.41M 10-Q · filed 2019-08-02 |
| 2019-03-31 | $36.69M 10-Q · filed 2019-04-29 |
| 2018-12-31 | $23.18M 10-K · filed 2020-02-27 |
| 2018-09-30 | $14.92M 10-Q · filed 2018-10-26 |
| 2018-06-30 | $15.89M 10-Q · filed 2018-08-03 |
| 2018-03-31 | $11.66M 10-Q · filed 2018-04-27 |
| 2017-12-31 | $9.66M 10-K · filed 2019-02-28 |
| 2017-09-30 | $8.65M 10-Q · filed 2017-10-31 |
| 2017-06-30 | $4.81M 10-Q · filed 2017-08-02 |
| 2017-03-31 | $14.72M 10-Q · filed 2017-05-04 |
| 2016-12-31 | $22.21M 10-K · filed 2018-02-26 |
| 2016-09-30 | $5.56M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $9.37M 10-Q · filed 2016-08-08 |
| 2016-03-31 | $7.69M 10-Q · filed 2016-05-02 |
| 2015-12-31 | $14.01M 10-K · filed 2017-02-27 |
| 2015-09-30 | $20.04M 10-Q · filed 2015-11-02 |
| 2015-06-30 | $21.96M 10-Q · filed 2015-08-05 |
| 2015-03-31 | $25.73M 10-Q · filed 2015-05-05 |
| 2014-12-31 | $15.90M 10-K · filed 2016-02-29 |
| 2013-12-31 | $59.00K 10-K · filed 2015-03-02 |
| 2012-03-31 | $3.27M 10-Q · filed 2012-04-30 |
| 2011-12-31 | $6.68M 10-Q · filed 2012-04-30 |
| 2011-09-30 | $1.54M 10-Q · filed 2011-10-31 |
| 2011-06-30 | $0.00 10-Q · filed 2011-08-01 |
| 2010-12-31 | $1.50M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |